CANNABIS-BASED WELLBEING, PAIN AND ANXIETY RELIEF
Cannadol Pharmaceuticals markets a range of natural cannabis-based products.
Our Products
Cannadol™ is a terpenoid-based cell-food that assists the body’s endocannabinoid system and the body’s immune system to help reduce pain, inflammation and anxiety. Cannadol is expected to be available from limited pharmacies in late 2023.
Cannapax™ is a future product that will assist with sleep management through its unique blend of essential oils in a hempseed oil base, peppermint oil and natural sweetener.
Cannadeine™ is a future product featuring a natural pain relief formula that can only be prescribed by medical professionals. It will contain a unique ratio of terpenes and cannabinoids, including Delta 9 THC that assists in alleviating pain and anxiety.
Medicinal cannabis
Medicinal cannabis was legalised in Australia on 30 October 2016. Australia is expected to be the 5th largest market in the world, worth A$1.3b in 2028 according to The Oceania Cannabis Report™.
Clinical trials
Throughout the world, clinical trials are being conducted to determine the positive effects of cannabinoids upon a range of disease states. These include epilepsy, MS, Parkinson’s disease, psychosis, depression, PTSD, anxiety, cancer, cardiovascular disease, chronic pain, fibromyalgia, Tourettes, ADHD, diabetes, migraine, insomnia, chemo-induced nausea and vomiting, and inflammatory bowel disease. The research is ever-evolving in this space. We are entering an exciting era where modern scientific evidence is emerging to support the use of cannabis as an effective and safe medicine for many chronic diseases.